课题基金 / 基金详情

MATERNAL DDAVP FOR TREATMENT OF OLIGOHYDRAMNIOS

MATERNAL DDAVP FOR TREATMENT OF OLIGOHYDRAMNIOS
母体 DDAVP 用于治疗水少症
批准号：
3742527
负责人：
MICHAEL G ROSS
金额：
$0.0万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3742527
关键词：
amniotic fluid arginine vasopressin body water hormone therapy human pregnant subject human therapy evaluation pregnancy disorder pregnancy disorder chemotherapy

项目摘要

项目成果

MICHAEL G ROSS的其他基金

相似基金

相关文献

中文摘要
翻译
母亲dDAVP对患者的潜在治疗价值
英文摘要
Potential therapeutic utility of maternal dDAVP for patients with oligohydramnios (insufficient amniotic fluid). Despite the significant consequences of oligohydramnios, there are no established means to increase amniotic fluid volume prior to labor. Recent studies indicate the potential of a novel treatment for oligohydramnios, utilizing maternal administration of a drug (dDAVP) to hydrate mother&secondly baby with amniotic fluid. The baby hydrates in relation to mother&increases its urine production and thus amniotic fluid.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RELATION OF PLASMA VOLUME EXPANSION TO VASOPRESSIN
FETAL ROLE IN OLIGOHYDRAMIOS
PRE-ECLAMPSIA--CLINICAL AND HORMONAL RESPONSE TO ANTEPARTUM VOLUME EXPANSION
RELATION OF PLASMA VOLUME EXPANSION TO VASOPRESSIN
海外基金